Group B Strept Assay for ARIES™ Sample-to-answer System
The Group B Streptococcus assay is the fifth planned for the launch menu of Luminex's new sample-to-answer system, ARIES™. The assay will complement Luminex's growing portfolio of ASR and IVD products. Previously announced items in the five assay launch menu targeted for the ARIES system include: Flu A/B and RSV, HSV 1&2, Norovirus, and Clostridium difficile.
ARIES GBS assay will deliver automated, sensitive results on Group B Strep, faster than culture methods, which can take several days for results and may require sub-culture to detect all strains. The ARIES GBS platform will deliver a streamlined workflow and generate rapid results with little hands-on time.
With a strong track record as an innovator and a leader in molecular diagnostics, Luminex Corporation will soon be the first company to offer multiplexed molecular panels as well as rapid, sample-to-answer testing with the introduction of its new ARIES system and menu of assays.
Watch the product video - info2.luminexcorp.com/aries
Not currently FDA cleared or CE-IVD marked.
Tags: Clostridium difficile, Influenza, Respiratory Syncytial Virus, Norovirus, Herpes Simplex Virus, Group B Streptococcus
Date Published: June 23, 2014
Source article link: Luminex Corporation » company contact details
Arup Offers Explify™ Respiratory a NGS Test for Respiratory Infections
New Primer Pairs for LDTs for P. jirovecii, Group C and G Strep
FDA Clearance for ARIES C. difficile Assay Detecting both Toxin A and B
CE-IVD Mark for Luminex ARIES® Norovirus Assay from Stool Specimens